Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Pharmacogenetics in Egyptian HCC Patients
NCT06527495Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Countries
- 1
- Sponsor
- Assiut University
- Modality
- Small Molecules
- Drugs
- sorafenib
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Assiut University. Primary endpoints: Vascular Endothelial Growth Factor A genotyping at 6 months and Kinase insert domain receptor genotyping at 6 months. Started Jan 2023; status: recruiting.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Adult patients with hepatocellular carcinoma who have not received prior systemic TKI therapy and do not have severe organ dysfunction or Child-Pugh grade C liver function.
04
Endpoints
Primary
Vascular Endothelial Growth Factor A genotyping
Kinase insert domain receptor genotyping
Secondary
Tumor markers
Beyond the preview
Go deeper on NCT06527495.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527495.